EVT-901
EVT-901
EVT-901 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications. It is primarily being studied for its effects on neurological disorders, particularly those involving neurodegeneration and cognitive impairment.
Chemical Structure and Properties[edit | edit source]
EVT-901 is a small molecule with a unique chemical structure that allows it to cross the blood-brain barrier effectively. Its molecular formula is C20H25N3O3, and it has a molecular weight of 355.43 g/mol. The compound is characterized by its high affinity for certain neurotransmitter receptors, which are believed to play a role in its mechanism of action.
Mechanism of Action[edit | edit source]
The precise mechanism of action of EVT-901 is still under investigation. However, preliminary studies suggest that it modulates the activity of neurotransmitter systems in the brain, particularly those involving dopamine and serotonin. This modulation is thought to enhance synaptic plasticity and improve cognitive function.
Clinical Trials[edit | edit source]
EVT-901 is currently in Phase II clinical trials. These trials are designed to evaluate its efficacy and safety in patients with Alzheimer's disease and other forms of dementia. Early results have shown promise, with some patients experiencing improvements in memory and cognitive abilities.
Potential Applications[edit | edit source]
Beyond its use in treating neurodegenerative diseases, EVT-901 is also being explored for its potential in treating mood disorders such as depression and anxiety. Its ability to modulate neurotransmitter systems makes it a candidate for a wide range of psychiatric conditions.
Side Effects and Safety[edit | edit source]
As with any investigational drug, EVT-901 has been associated with some side effects. The most commonly reported adverse effects include nausea, headache, and dizziness. Long-term safety data is still being collected, and researchers are closely monitoring trial participants for any serious adverse events.
Regulatory Status[edit | edit source]
EVT-901 has not yet been approved by any regulatory agency. It is currently classified as an investigational drug, and its use is restricted to clinical trial settings. The results of ongoing trials will determine its future regulatory status.
Research and Development[edit | edit source]
The development of EVT-901 is being spearheaded by a collaboration between several pharmaceutical companies and academic institutions. This partnership aims to accelerate the drug's development and bring it to market if it proves to be safe and effective.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
